Fed. Circ. Upholds Rejection Of 2 Endo Opana Patents
The Federal Circuit on Friday revived a nixed Endo Pharmaceuticals Inc. drug patent application related to a formulation of the painkiller Opana, but affirmed the U.S. Patent and Trademark Office's rejection...To view the full article, register now.
Already a subscriber? Click here to view full article